A detailed history of Black Rock Inc. transactions in Equillium, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 38,317 shares of EQ stock, worth $23,373. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,317
Previous 3,811 905.43%
Holding current value
$23,373
Previous $8,000 225.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.66 - $2.33 $22,773 - $80,398
34,506 Added 905.43%
38,317 $26,000
Q1 2024

May 10, 2024

SELL
$0.73 - $3.0 $8 - $36
-12 Reduced 0.31%
3,811 $8,000
Q4 2023

Feb 13, 2024

SELL
$0.48 - $0.74 $2,881 - $4,442
-6,003 Reduced 61.09%
3,823 $2,000
Q3 2023

Nov 13, 2023

BUY
$0.72 - $0.9 $73 - $91
102 Added 1.05%
9,826 $7,000
Q2 2023

Aug 11, 2023

SELL
$0.49 - $0.79 $21,718 - $35,015
-44,324 Reduced 82.01%
9,724 $7,000
Q1 2023

May 12, 2023

BUY
$0.56 - $1.24 $735 - $1,628
1,313 Added 2.49%
54,048 $39,000
Q4 2022

Feb 13, 2023

BUY
$0.83 - $2.26 $7,051 - $19,200
8,496 Added 19.2%
52,735 $55,000
Q3 2022

Nov 14, 2022

SELL
$1.93 - $3.14 $11,346 - $18,460
-5,879 Reduced 11.73%
44,239 $98,000
Q2 2022

Aug 12, 2022

BUY
$1.69 - $3.26 $18,284 - $35,269
10,819 Added 27.53%
50,118 $102,000
Q1 2022

May 12, 2022

SELL
$2.99 - $4.19 $4,332 - $6,071
-1,449 Reduced 3.56%
39,299 $123,000
Q4 2021

Feb 10, 2022

SELL
$3.77 - $6.99 $7,702 - $14,280
-2,043 Reduced 4.77%
40,748 $154,000
Q3 2021

Nov 09, 2021

SELL
$4.84 - $6.91 $3,334 - $4,760
-689 Reduced 1.58%
42,791 $292,000
Q2 2021

Aug 11, 2021

BUY
$5.11 - $7.64 $222,182 - $332,187
43,480 New
43,480 $256,000

Others Institutions Holding EQ

About Equillium, Inc.


  • Ticker EQ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,352,100
  • Market Cap $21M
  • Description
  • Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...
More about EQ
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.